A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
Latest Information Update: 21 Sep 2026
At a glance
- Drugs KD 496 (Primary)
- Indications Gastric cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 14 Sep 2026 Planned End Date changed from 15 Nov 2026 to 15 Nov 2027.
- 14 Sep 2026 Planned primary completion date changed from 30 Jun 2026 to 30 Jun 2027.
- 14 Sep 2026 Status changed from not yet recruiting to recruiting.